These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 6313012

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
    Robinson MJ, Osheroff N.
    Biochemistry; 1990 Mar 13; 29(10):2511-5. PubMed ID: 2159323
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures.
    Wilson WR, Giesbrecht JL, Hill RP, Whitmore GF.
    Cancer Res; 1981 Jul 13; 41(7):2809-16. PubMed ID: 6894713
    [Abstract] [Full Text] [Related]

  • 28. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
    Coates AS, Bishop J, Mann GJ, Raghavan D.
    Eur J Cancer Clin Oncol; 1986 Jan 13; 22(1):97-100. PubMed ID: 3754214
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Multiple ventricular extrasystoles following administration of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA).
    Falkson G.
    Cancer Treat Rep; 1980 Jan 13; 64(2-3):358. PubMed ID: 6157470
    [No Abstract] [Full Text] [Related]

  • 34. Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
    Baguley BC, Denny WA, Atwell GJ, Cain BF.
    J Med Chem; 1981 May 13; 24(5):520-5. PubMed ID: 6894620
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
    Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G.
    J Pharmacol Exp Ther; 2013 Feb 13; 344(2):467-78. PubMed ID: 23192654
    [Abstract] [Full Text] [Related]

  • 38. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
    Bowden GT, Roberts R, Alberts DS, Peng YM, Garcia D.
    Cancer Res; 1985 Oct 13; 45(10):4915-20. PubMed ID: 4027978
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
    Warrell RP, Straus DJ, Young CW.
    Cancer Treat Rep; 1980 Oct 13; 64(10-11):1157-8. PubMed ID: 6893952
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.